Tag Archive for: IQVIA

The delay follows a lawsuit filed by the FTC last week seeking to block the proposed merger between the two companies, alleging that the deal would sharply reduce competition in healthcare programmatic advertising “by combining two of the top three providers” in the space.

“Competition in this market is necessary to protect patients from higher health care prices that could be passed on if the cost of marketing health care products increases due to reduced competition. The FTC contends the deal would also reduce innovation in this emerging industry, potentially harming patients by preventing doctors and other health care practitioners from learning about useful pharmaceutical products,” the FTC states.

The healthcare marketing and analytics leader expands their Measurement Suite to include unprecedented audience and campaign insights.

Managing regulatory information in the pharmaceutical industry is challenging in post-pandemic Europe. The introduction of new requirements surrounding substances, products, organizations, and referential (SPOR) data and a new shared target operating model (TOM) across Industry and regulators are forcing companies to rethink their approach to managing regulatory information and submissions. This is driving new data management initiatives to align existing regulatory data with master data systems, streamline data submissions, and improve data maintenance capabilities, according to Jens-Olaf Vanggaard, senior director, Global Safety, Regulatory & Quality Solutions, IQVIA.

Adopting digital transformation is now an industry standard for success – but what precisely does that mean for the clinical development landscape? Gary Shorter, Head of Artificial Intelligence at IQVIA, explores the answers.

As organizations continue to evaluate and implement automation and AI technology, it is important to consider how increased use of technology should align with both industry best practices and regulations – and to proactively address how technology adoption will impact stakeholders involved in routine pharmacovigilance activities while ensuring deployment and implementation poses no risk to breaching guidelines or regulations.